NCT00569868View on ClinicalTrials.gov

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
MULTIPLE MYELOMA
Interventions
DRUG

Velcade

"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00569868 - UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter